LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. AU="Oyelese, Yinka"
  2. AU="Jean-Pierre SarthouauthorToulouse University, ENSAT, UMR 1248 AGIR, Castanet-Tolosan F-31326, FranceINRA, UMR 1248 AGIR, Chemin de Borde-Rouge, Castanet-Tolosan F-31326, France"

Search results

Result 1 - 10 of total 83

Search options

  1. Article ; Online: A 2-cm Distance Should Not Be Used to Define Vasa Previa.

    Oyelese, Yinka

    Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine

    2024  Volume 43, Issue 4, Page(s) 811–814

    MeSH term(s) Female ; Humans ; Pregnancy ; Vasa Previa/diagnostic imaging ; Placenta/diagnostic imaging ; Umbilical Cord/diagnostic imaging ; Ultrasonography, Prenatal ; Placenta Previa
    Language English
    Publishing date 2024-01-31
    Publishing country England
    Document type Journal Article
    ZDB-ID 604829-8
    ISSN 1550-9613 ; 0278-4297
    ISSN (online) 1550-9613
    ISSN 0278-4297
    DOI 10.1002/jum.16420
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Vasa Previa: Outpatient management in low-risk asymptomatic patients is reasonable.

    Oyelese, Yinka

    European journal of obstetrics, gynecology, and reproductive biology

    2023  Volume 293, Page(s) 167–168

    MeSH term(s) Humans ; Female ; Pregnancy ; Vasa Previa/diagnostic imaging ; Vasa Previa/therapy ; Outpatients ; Prenatal Diagnosis ; Ultrasonography, Prenatal ; Risk
    Language English
    Publishing date 2023-12-14
    Publishing country Ireland
    Document type Letter
    ZDB-ID 190605-7
    ISSN 1872-7654 ; 0301-2115 ; 0028-2243
    ISSN (online) 1872-7654
    ISSN 0301-2115 ; 0028-2243
    DOI 10.1016/j.ejogrb.2023.12.017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Gestational hypertension: time for a new name?

    Oyelese, Yinka

    American journal of obstetrics and gynecology

    2023  Volume 230, Issue 3, Page(s) e17

    MeSH term(s) Pregnancy ; Female ; Humans ; Hypertension, Pregnancy-Induced/diagnosis ; Hypertension/epidemiology ; Blood Pressure ; NG-Nitroarginine Methyl Ester ; Nitric Oxide ; Enzyme Inhibitors
    Chemical Substances NG-Nitroarginine Methyl Ester (V55S2QJN2X) ; Nitric Oxide (31C4KY9ESH) ; Enzyme Inhibitors
    Language English
    Publishing date 2023-08-25
    Publishing country United States
    Document type Letter
    ZDB-ID 80016-8
    ISSN 1097-6868 ; 0002-9378
    ISSN (online) 1097-6868
    ISSN 0002-9378
    DOI 10.1016/j.ajog.2023.08.020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Randomized controlled trials: not always the "gold standard" for evidence in obstetrics and gynecology.

    Oyelese, Yinka

    American journal of obstetrics and gynecology

    2023  Volume 230, Issue 4, Page(s) 417–425

    Abstract: Randomized controlled trials are considered the "gold standard" for therapeutic interventions, and it is not uncommon for sweeping changes in medical practice to follow positive results from such trials. However, randomized controlled trials are not ... ...

    Abstract Randomized controlled trials are considered the "gold standard" for therapeutic interventions, and it is not uncommon for sweeping changes in medical practice to follow positive results from such trials. However, randomized controlled trials are not without their limitations. Physicians frequently view randomized controlled trials as infallible, whereas they tend to dismiss evidence derived from sources other than randomized controlled trials as less credible or reliable. In several situations in obstetrics and gynecology, there are no randomized controlled trials to help guide the clinician. In these circumstances, it is important to evaluate the entire body of evidence including observational studies, rather than dismiss interventions altogether simply because no randomized controlled trials exist. Randomized controlled trials and observational studies should be viewed as complementary rather than at odds with each other. Some reversals in widely adopted clinical practice have recently been implemented following subsequent studies that contradicted the outcomes of major randomized controlled trials. The most notable of these was the withdrawal from the market of 17-hydroxyprogesterone caproate for preterm birth prevention. Such reversals could potentially have been averted if the inherent limitations of randomized controlled trials were carefully considered before implementing these universal practice changes. This Clinical Opinion underscores the limitations of an exclusive reliance on randomized controlled trials while disregarding other evidence in determining how best to care for patients. Solutions are proposed that advocate that clinicians adopt a more balanced perspective that considers the entirety of the available medical evidence and the individual patient characteristics, needs, and wishes.
    MeSH term(s) Female ; Humans ; Infant, Newborn ; Gynecology ; Obstetrics ; Premature Birth/prevention & control ; Randomized Controlled Trials as Topic ; Pregnancy
    Language English
    Publishing date 2023-10-12
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80016-8
    ISSN 1097-6868 ; 0002-9378
    ISSN (online) 1097-6868
    ISSN 0002-9378
    DOI 10.1016/j.ajog.2023.10.015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Prenatal Screening and Diagnosis: Time for a Paradigm Shift.

    Oyelese, Yinka / Schioppo, Davia / O'Brien, Barbara M

    American journal of perinatology

    2024  

    Abstract: Recent advances in genetics and imaging have ushered in substantial breakthroughs in screening and diagnosis for chromosomal and structural abnormalities. Thus, it is imperative that healthcare providers caring for pregnant individuals should re-examine ... ...

    Abstract Recent advances in genetics and imaging have ushered in substantial breakthroughs in screening and diagnosis for chromosomal and structural abnormalities. Thus, it is imperative that healthcare providers caring for pregnant individuals should re-examine established practices in prenatal screening and diagnosis. In the past, screening for chromosomal abnormalities was based almost entirely on Down syndrome. Pregnant individuals aged > 35 were considered at "high risk" or of "advanced maternal age" based on age alone; however, the advent of tests with high sensitivity for prenatal detection of chromosomal abnormalities should lead to abandoning that concept, at least from the perspective of chromosomal abnormalities. Given that first-trimester and second-trimester screening will fail to detect between 5 and 20% of Down syndrome, in most situations, non-invasive testing with cell-free DNA should be the first-line screen for Down syndrome. The fact that over 99% of fetuses with Down syndrome will be detected prenatally with cell-free DNA gives other fetal chromosomal and structural abnormalities increasing prominence. Chromosomal microarray analysis (CMA) permits prenatal detection of several clinically important chromosomal aberrations that cannot be detected by karyotype and may exist in structurally normal fetuses with low-risk cell-free DNA screening. As such, CMA should be more readily conducted when invasive testing is performed, regardless of the presence of a structural abnormality. Isolated sonographic "soft markers" have no clinical significance in patients who have normal cell-free DNA screening, can cause unwarranted anxiety and a negative impact on pregnancy, and perhaps it is time to stop discussing them. Detailed first-trimester ultrasound allows early detection of several severe fetal anomalies, and therefore in settings with adequately trained personnel and resources, should be used more frequently. This Opinion traces the evolution of prenatal screening and diagnosis and advocates for a paradigm shift that aligns with recent developments in prenatal screening and diagnostic capabilities.
    Language English
    Publishing date 2024-04-24
    Publishing country United States
    Document type Journal Article
    ZDB-ID 605671-4
    ISSN 1098-8785 ; 0735-1631
    ISSN (online) 1098-8785
    ISSN 0735-1631
    DOI 10.1055/a-2312-8824
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Perinatal Mortality Despite Prenatal Diagnosis of Vasa Previa: A Systematic Review.

    Oyelese, Yinka / Javinani, Ali / Shamshirsaz, Alireza A

    Obstetrics and gynecology

    2024  Volume 143, Issue 2, Page(s) e22

    MeSH term(s) Female ; Humans ; Pregnancy ; Perinatal Death ; Perinatal Mortality ; Prenatal Diagnosis ; Vasa Previa/diagnostic imaging
    Language English
    Publishing date 2024-01-16
    Publishing country United States
    Document type Systematic Review ; Journal Article
    ZDB-ID 207330-4
    ISSN 1873-233X ; 0029-7844
    ISSN (online) 1873-233X
    ISSN 0029-7844
    DOI 10.1097/AOG.0000000000005486
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Vasa previa: time to make a difference.

    Oyelese, Yinka

    American journal of obstetrics and gynecology

    2018  Volume 221, Issue 6, Page(s) 539–541

    MeSH term(s) Female ; Humans ; Pregnancy ; Retrospective Studies ; Ultrasonography, Prenatal ; Vasa Previa
    Language English
    Publishing date 2018-03-24
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 80016-8
    ISSN 1097-6868 ; 0002-9378
    ISSN (online) 1097-6868
    ISSN 0002-9378
    DOI 10.1016/j.ajog.2019.08.034
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Prenatally Diagnosed Vasa Previa: A Single-Institution Series of 96 Cases.

    Oyelese, Yinka

    Obstetrics and gynecology

    2017  Volume 129, Issue 3, Page(s) 581–582

    MeSH term(s) Female ; Health Facilities ; Humans ; Pregnancy ; Prenatal Diagnosis ; Ultrasonography, Prenatal ; Umbilical Cord ; Vasa Previa
    Language English
    Publishing date 2017-01-24
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207330-4
    ISSN 1873-233X ; 0029-7844
    ISSN (online) 1873-233X
    ISSN 0029-7844
    DOI 10.1097/AOG.0000000000001919
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Vasa Previa.

    Oyelese, Yinka / Javinani, Ali / Shamshirsaz, Alireza A

    Obstetrics and gynecology

    2023  Volume 142, Issue 3, Page(s) 503–518

    Abstract: Vasa previa refers to unprotected fetal vessels running through the membranes over the cervix. Until recently, this condition was associated with an exceedingly high perinatal mortality rate attributable to fetal exsanguination when the membranes ... ...

    Abstract Vasa previa refers to unprotected fetal vessels running through the membranes over the cervix. Until recently, this condition was associated with an exceedingly high perinatal mortality rate attributable to fetal exsanguination when the membranes ruptured. However, ultrasonography has made it possible to diagnose the condition prenatally, allowing cesarean delivery before labor or rupture of the membranes. Several recent studies have indicated excellent outcomes with prenatally diagnosed vasa previa. However, outcomes continue to be dismal when vasa previa is undiagnosed before labor. Risk factors for vasa previa include second-trimester placenta previa and low-lying placentas, velamentous cord insertion, placentas with accessory lobes, in vitro fertilization, and multifetal gestations. Recognition of individuals who are at risk and screening them will greatly decrease the mortality rate from this condition. Because of the relative rarity of vasa previa, there are no randomized controlled trials to guide management. Therefore, recommendations on the diagnosis and management of vasa previa are based largely on cohort studies and expert opinion. This Clinical Expert Series review addresses the epidemiology, pathophysiology, natural history, diagnosis and management of vasa previa, as well as innovative treatments for the condition.
    MeSH term(s) Female ; Pregnancy ; Humans ; Vasa Previa/diagnostic imaging ; Cesarean Section ; Fertilization in Vitro ; Fetus ; Labor, Obstetric
    Language English
    Publishing date 2023-08-03
    Publishing country United States
    Document type Journal Article
    ZDB-ID 207330-4
    ISSN 1873-233X ; 0029-7844
    ISSN (online) 1873-233X
    ISSN 0029-7844
    DOI 10.1097/AOG.0000000000005287
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Prenatal Screening and Diagnosis: Time for a Paradigm Shift

    Oyelese, Yinka / Schioppo, Davia / O'Brien, Barbara M

    American Journal of Perinatology

    2024  

    Abstract: Recent advances in genetics and imaging have ushered in substantial breakthroughs in screening and diagnosis for chromosomal and structural abnormalities. Thus, it is imperative that healthcare providers caring for pregnant individuals should re-examine ... ...

    Abstract Recent advances in genetics and imaging have ushered in substantial breakthroughs in screening and diagnosis for chromosomal and structural abnormalities. Thus, it is imperative that healthcare providers caring for pregnant individuals should re-examine established practices in prenatal screening and diagnosis. In the past, screening for chromosomal abnormalities was based almost entirely on Down syndrome. Pregnant individuals aged > 35 were considered at “high risk” or of “advanced maternal age” based on age alone; however, the advent of tests with high sensitivity for prenatal detection of chromosomal abnormalities should lead to abandoning that concept, at least from the perspective of chromosomal abnormalities. Given that first-trimester and second-trimester screening will fail to detect between 5 and 20% of Down syndrome, in most situations, non-invasive testing with cell-free DNA should be the first-line screen for Down syndrome. The fact that over 99% of fetuses with Down syndrome will be detected prenatally with cell-free DNA gives other fetal chromosomal and structural abnormalities increasing prominence. Chromosomal microarray analysis (CMA) permits prenatal detection of several clinically important chromosomal aberrations that cannot be detected by karyotype and may exist in structurally normal fetuses with low-risk cell-free DNA screening. As such, CMA should be more readily conducted when invasive testing is performed, regardless of the presence of a structural abnormality. Isolated sonographic “soft markers” have no clinical significance in patients who have normal cell-free DNA screening, can cause unwarranted anxiety and a negative impact on pregnancy, and perhaps it is time to stop discussing them. Detailed first-trimester ultrasound allows early detection of several severe fetal anomalies, and therefore in settings with adequately trained personnel and resources, should be used more frequently. This Opinion traces the evolution of prenatal screening and diagnosis and advocates for a paradigm shift that aligns with recent developments in prenatal screening and diagnostic capabilities.
    Language English
    Publishing date 2024-04-24
    Publisher Thieme Medical Publishers, Inc.
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 605671-4
    ISSN 1098-8785 ; 0735-1631
    ISSN (online) 1098-8785
    ISSN 0735-1631
    DOI 10.1055/a-2312-8824
    Database Thieme publisher's database

    More links

    Kategorien

To top